MP 1032

Drug Profile

MP 1032

Alternative Names: MP1032

Latest Information Update: 31 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MetrioPharm
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Macrophage modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis

Most Recent Events

  • 14 Mar 2017 MetrioPharm plans a phase IIb trial for Plaque psoriasis
  • 14 Mar 2017 Positive top-line safety and efficacy data from a phase IIa trial in Plaque psoriasis released by MetrioPharm
  • 01 Feb 2017 MetrioPharm completes a phase II trial in Plaque psoriasis in Germany (NCT02908347) (EudraCT2015-005159-28)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top